# MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric Cancer

> **NCT02007148** · PHASE2 · UNKNOWN · sponsor: **International Group of Endovascular Oncology** · enrollment: 51 (estimated)

## Conditions studied

- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** capecitabine
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT02007148
- **Lead sponsor:** International Group of Endovascular Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-11
- **Primary completion:** 2021-10
- **Final completion:** 2022-05
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2019-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02007148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02007148, "MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02007148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*